These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35491124)

  • 1. TM5614, an Inhibitor of Plasminogen Activator Inhibitor-1, Exerts an Antitumor Effect on Chronic Myeloid Leukemia.
    Sasaki K; Fujiwara T; Ochi T; Ono K; Kato H; Onodera K; Ichikawa S; Fukuhara N; Onishi Y; Yokoyama H; Miyata T; Harigae H
    Tohoku J Exp Med; 2022 Jun; 257(3):211-224. PubMed ID: 35491124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor.
    Takahashi N; Kameoka Y; Onizuka M; Onishi Y; Takahashi F; Dan T; Miyata T; Ando K; Harigae H
    Cancer Med; 2023 Feb; 12(4):4250-4258. PubMed ID: 36151699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells.
    Yahata T; Ibrahim AA; Hirano KI; Muguruma Y; Naka K; Hozumi K; Vaughan DE; Miyata T; Ando K
    Haematologica; 2021 Feb; 106(2):483-494. PubMed ID: 32001531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
    Neviani P; Harb JG; Oaks JJ; Santhanam R; Walker CJ; Ellis JJ; Ferenchak G; Dorrance AM; Paisie CA; Eiring AM; Ma Y; Mao HC; Zhang B; Wunderlich M; May PC; Sun C; Saddoughi SA; Bielawski J; Blum W; Klisovic RB; Solt JA; Byrd JC; Volinia S; Cortes J; Huettner CS; Koschmieder S; Holyoake TL; Devine S; Caligiuri MA; Croce CM; Garzon R; Ogretmen B; Arlinghaus RB; Chen CS; Bittman R; Hokland P; Roy DC; Milojkovic D; Apperley J; Goldman JM; Reid A; Mulloy JC; Bhatia R; Marcucci G; Perrotti D
    J Clin Invest; 2013 Oct; 123(10):4144-57. PubMed ID: 23999433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
    Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
    Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
    J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review.
    Al Hamad M
    F1000Res; 2021; 10():1288. PubMed ID: 35284066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
    Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
    Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
    Aljedai A; Buckle AM; Hiwarkar P; Syed F
    PLoS One; 2015; 10(4):e0123016. PubMed ID: 25849484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS; Liu DS; Dai CW; Li RJ
    Am J Hematol; 2006 Apr; 81(4):242-55. PubMed ID: 16550520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.
    Burslem GM; Schultz AR; Bondeson DP; Eide CA; Savage Stevens SL; Druker BJ; Crews CM
    Cancer Res; 2019 Sep; 79(18):4744-4753. PubMed ID: 31311809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
    Aichberger KJ; Mayerhofer M; Krauth MT; Vales A; Kondo R; Derdak S; Pickl WF; Selzer E; Deininger M; Druker BJ; Sillaber C; Esterbauer H; Valent P
    Cancer Res; 2005 Oct; 65(20):9436-44. PubMed ID: 16230407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status.
    Cea M; Cagnetta A; Cirmena G; Garuti A; Rocco I; Palermo C; Pierri I; Reverberi D; Nencioni A; Ballestrero A; Gobbi M; Carella AM; Patrone F
    Leuk Lymphoma; 2013 Feb; 54(2):342-52. PubMed ID: 22762548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
    Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
    J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapeutic advances for chronic myelogenous leukemia: beyond tyrosine kinase inhibitors.
    Costa A; Scalzulli E; Carmosino I; Ielo C; Bisegna ML; Martelli M; Breccia M
    Expert Opin Pharmacother; 2024 Feb; 25(2):189-202. PubMed ID: 38488824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.